Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers.
Phase of Trial: Phase I
Latest Information Update: 07 May 2014
At a glance
- Drugs RG 4733 (Primary) ; Temsirolimus (Primary)
- Indications Endometrial cancer; Renal cell carcinoma; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 07 Oct 2013 Planned end date changed from 1 May 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
- 23 Sep 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
- 26 Mar 2013 Planned end date changed from 1 Jul 2011 to 1 May 2013 as reported by ClinicalTrials.gov.